Indian pharma seeing record VC investment and significant deal-making
The life sciences sector is in the news again in India and has entered the top league. The pharmaceuticals and healthcare sector recorded the second highest value of private equity and venture capital investments in November at $1.2 billion. This also happens to be the sector’s highest-ever value of private equity investment in a month, signalling the trajectory of the Indian life sciences industry, reports The Pharma Letter’s India correspondent.
Several locked-in trends like demographic, regulatory, technological and financial are shifting the trajectory of the industry. With a record 140 million households expected to enter the middle class in the next decade, consumption of healthcare services is set to increase.
Complex generics and biosimilars are set to be key growth drivers for the pharma industry, marking a shift away from the more commoditized generics that have historically dominated the Indian life sciences sector.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze